Panel A shows histograms of CTV dilution in splenocytes after treatment with PBS, wtIL-2, and 1G12 at different doses. The x-axis represents CTV, and the y-axis represents cell count. Panel B consists of two box plots showing the fold change over PBS in Foxp3 MFI and CTLA-4 MFI in splenocytes after treatment with PBS, 1G12, and wtIL-2 at different doses. The x-axis represents treatment groups, and the y-axis represents fold change over PBS. Panel C includes two bar graphs showing CD25 MFI and Treg numbers in pancLN after treatment with PBS, 1G12, and wtIL-2 at different doses. The x-axis represents treatment groups, and the y-axis represents fold change over PBS. Panel D shows a bar graph of CD25 MFI in islets after treatment with PBS, 1G12, and wtIL-2 at different doses. The x-axis represents treatment groups, and the y-axis represents fold change over PBS. Panel E includes three bar graphs showing CD25 MFI in host Tregs, CD4s, and CD8s in pancLN after treatment with PBS, 1G12, and wtIL-2 at different doses. The x-axis represents treatment groups, and the y-axis represents fold change over PBS. The graphs illustrate the effects of different treatments on the expression of various markers in Tregs and other immune cells.
OrthoIL-2 1G12 on orthoIL-2R engineered Tregs (related to Fig. 3). (A and B) A mixture of orthoIL-2R–transduced Thy1.1+ and non-transduced Thy1.1− NOD Tregs were transferred to NSG mice (200,000/mouse). (A) Mice received daily i.p. injection of PBS, MSA-1G12, or MSA-wtIL-2 at dose indicated (MSA is denoted by *). Spleens were collected on day 3 after transfer for assessing CTV dilution. (B) Mice were treated with MSA-1G12 or MSA-wtIL-2 at the dose indicated. Spleens were collected on day 8 to assess Foxp3 and CTLA-4 expression. Ordinary two-way ANOVA followed by Sidak multiple comparison test was used to determine the statistical significance. (C–E) FACS-purified orthoIL-2(+) BDC2.5 Tregs were transferred to 5-wk-old prediabetic NOD.CD28KO mice followed by seven daily i.p. injections of PBS, MSA-3A10, or MSA-wtIL-2 at the dose indicated on the graph. (C) CD25 expression on orthoIL-2(+) and total number of orthoIL-2R(+) Tregs in the pancLN. (D) CD25 expression on orthoIL-2(+) cell in the islets. (E) CD25 expression on host T cells in pancLN. Kruskal–Wallis test was used to determine the statistical significance of the difference with PBS controls. Only statistically significant P values are listed.